Teitur Trophics is a biotech company, established in January 2020, aiming to treat chronic neurological disorders with a special focus on Huntington’s disease (HD). Through state-of-the-art peptide technology, Teitur has developed a first-in-class disease-modifying peptides that targets several key pathologies in HD. Through subcutaneous delivery, the peptide enters the bloodstream and subsequently crosses the blood-brain-barrier to reach affected brain regions where it promotes survival of neurons and removal of toxic protein aggregates. In addition to our lead program, Teitur has several exciting programs in pipeline, targeting different neurological disorders.
Established in 2020.